PHMB 0.08% — Competitive Intelligence Brief

PHMB 0.08% (PHMB 0.08%) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimicrobial. Area: Dermatology.

phase 3 Antimicrobial Dermatology Small molecule

Target snapshot

PHMB 0.08% (PHMB 0.08%) — SIFI SpA. PHMB is an antimicrobial agent that works by disrupting the cell membrane of microorganisms.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
PHMB 0.08% TARGET	PHMB 0.08%	SIFI SpA	phase 3	Antimicrobial
Fexinidazole	FEXINIDAZOLE	Sanofi	marketed	Nitroimidazole Antimicrobial [EPC]		2021-01-01
Solosec	SECNIDAZOLE	Evofem Inc	marketed	Nitroimidazole Antimicrobial [EPC]		2017-01-01
Xtoro	FINAFLOXACIN	Fonseca Biosciences	marketed	Quinolone Antimicrobial		2014-01-01
Besivance	BESIFLOXACIN	Bausch Health	marketed	Quinolone Antimicrobial [EPC]		2009-01-01
Pylera	BISMUTH SUBCITRATE		marketed	Nitroimidazole Antimicrobial [EPC]		2006-01-01
BISMUTH SUBCITRATE POTASSIUM	BISMUTH SUBCITRATE POTASSIUM		marketed	Nitroimidazole Antimicrobial [EPC]		2006-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimicrobial class)

1. Armata Pharmaceuticals, Inc. · 2 drugs in this class
2. Krishnadevaraya College of Dental Sciences & Hospital · 1 drug in this class
3. NovaBay Pharmaceuticals, Inc. · 1 drug in this class
4. Riyadh Colleges of Dentistry and Pharmacy · 1 drug in this class
5. SIFI SpA · 1 drug in this class
6. Savara Inc. · 1 drug in this class
7. Universitair Ziekenhuis Brussel · 1 drug in this class
8. University of Guarulhos · 1 drug in this class
9. VA Office of Research and Development · 1 drug in this class